EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Development and validation of a high-throughput agglutination assay for O-serogrouping clinical Escherichia coli isolates

Ritu Shastry, Wenchi Shang, Sarah Janssen, Sarah Tete, Elizabeth Garcia Dominguez, Germie van den Dobbelsteen iD, Todd Davies, Brian Morrow iD

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.00991-26 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Ritu Shastry und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA. Hauptthemen laut MEDLINE: Agglutination Tests, Serotyping, High-Throughput Screening Assays, Escherichia coli. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate O-serotyping of Escherichia coli remains essential for clinical surveillance, outbreak investigation, and evaluation of vaccines targeting invasive E. coli disease. Traditional agglutination-based serotyping is labor-intensive, low-throughput, and reliant on subjective visual interpretation. We developed a high-throughput (HTP) 96-well agglutination assay incorporating automated OD normalization (BioTek Epoch) and objective agglutination quantification using a CTL ImmunoSpot reader. A data-driven positivity cutoff (Total Intensity of Spots per Well < 11.65) was established via Youden’s index to optimize diagnostic discrimination. Validation was performed in a GCLP-compliant laboratory using clinical isolates representing the nine O-serogroups included in the ExPEC9V vaccine candidate. The assay demonstrated 100% sensitivity across all homologous O-serogroups ( n = 9) and ≥95% specificity across heterologous O-serogroups, including five non-ExPEC9V clinical isolates. Robustness was confirmed for bacterial suspensions with OD 600 values of 0.6–1.2, the range recommended for clinical implementation. Long-term stability of boiled cultures stored at 2–8°C was inconsistent—particularly for O75 antisera—supporting same-day preparation of suspensions. Due to heat-associated interference observed with deep-well plastic blocks, glass 96-well tube systems were validated and adopted for clinical testing, demonstrating 100% specificity across all heterologous O-serogroups. This validated HTP agglutination assay provides a scalable, reproducible, and clinically actionable method for E. coli O-serotyping. By preserving the immunologic specificity of conventional agglutination while enabling automation and objective readouts, the assay is well suited for vaccine efficacy studies, reference laboratory workflows, and clinical microbiology programs requiring accurate phenotypic confirmation of O-antigen expression. IMPORTANCE Agglutination serotyping of bacterial isolates is labor-intensive, requires specialized laboratories and skilled personnel, and relies on subjective visual interpretation. Nevertheless, it remains essential for determining O-antigen expression, providing information that molecular methods—focused only on detecting serotype-specific genes—cannot. For this reason, agglutination O-serotyping continues to serve as the regulatory accepted gold standard. This study describes the development, optimization, and validation of a high-throughput agglutination O-serotyping assay designed to overcome the constraints of low throughput and operator-dependent variability. The validated assay demonstrated its scientific utility through the characterization of clinical isolates from a Phase 3 trial of a candidate Escherichia coli vaccine. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT04899336.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agglutination TestsSerotypingHigh-Throughput Screening AssaysEscherichia coliO AntigensEscherichia coli InfectionsHumansSensitivity and SpecificitySerogroup

Stichwörter der Autor:innen

Escherichia coliclinical validationhigh-throughput O-serotyping

Substanzen

O Antigens

Autor:innen und Institutionen

  • Bacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA.
  • Discovery and Manufacturing Statistics, Johnson & Johnson Innovative Medicine, Archimedesweg, Leiden, the Netherlands.
  • Bacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Archimedesweg, Leiden, the Netherlands.

ORCID-Profile: Germie van den Dobbelsteen, Brian Morrow

Zitieren

APA

Shastry, R., Shang, W., Janssen, S., Tete, S., Dominguez, E. G., van den Dobbelsteen, G., Davies, T., & Morrow, B. (2026). Development and validation of a high-throughput agglutination assay for O-serogrouping clinical Escherichia coli isolates. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00991-26

Vancouver

Shastry R, Shang W, Janssen S, Tete S, Dominguez EG, van den Dobbelsteen G, et al. Development and validation of a high-throughput agglutination assay for O-serogrouping clinical Escherichia coli isolates. Microbiology Spectrum. 2026. doi:10.1128/spectrum.00991-26

BibTeX
@article{Shastry2026,
  author = {Shastry, Ritu and Shang, Wenchi and Janssen, Sarah and Tete, Sarah and Dominguez, Elizabeth Garcia and van den Dobbelsteen, Germie and Davies, Todd and Morrow, Brian},
  title = {Development and validation of a high-throughput agglutination assay for O-serogrouping clinical Escherichia coli isolates},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.00991-26}
}
Kostenlos starten →